The round was co-led by new investors, Farallon Capital and Hadean Ventures. MSD (tradename of Merck and Co., Inc., Kenilworth, N.J., USA) and Adjuvant Capital, as well as current investors Global Health Investment Fund, aws Gruenderfonds, Omnes Capital, Ventech and Wellington Partners Life Sciences, also participated.
The proceeds from this Series D round will be used to accelerate the company's pivotal Phase 3 clinical trial program for its Chikungunya vaccine and to support further expansion into oncology indications using its proprietary measles vaccine vector platform.
Concurrent with the financing, Dr. Walter Stockinger, Managing Partner at Hadean Ventures, will join Themis' Supervisory Board.
Themis' lead programme is a vaccine for Chikungunya, a debilitating disease with global outbreak potential, developed using its measles vaccine vector platform.
The vaccine candidate, MV-CHIK, is Phase 3-ready with the pivotal global Phase 3 trial initiation expected in the next few months.
The company's other vaccine programmes include those for Zika and Lassa Fever, which are currently being studied in Phase 1 clinical trials, and for Respiratory Syncytial Virus, Cytomegalovirus, Norovirus and Middle East Respiratory Syndrome, which are in pre-clinical studies.
Themis recently announced a collaboration with MSD to develop undisclosed vaccine candidates.
In 2018, the company initiated its immuno-oncology portfolio with the first therapeutic candidate to enter clinical studies this year.
Farallon Capital Management, L.L.C. is a global institutional investment management firm founded in 1986. Farallon manages approximately USD 28bn in capital for institutions, including college endowments, charitable foundations, pension plans and sovereign wealth funds, and for high net worth individuals.
Farallon is headquartered in San Francisco and has offices in London, Singapore, Hong Kong, Tokyo and São Paulo.
Hadean Ventures is an Oslo and Stockholm-based life science fund manager that invests in life science companies across Europe with a particular focus on under-ventured regions. Hadean's funds are backed by leading European and US-based private and institutional investors.
Adjuvant is a New York-based life sciences fund built to accelerate the development of new technologies for the world's most pressing public health challenges.
Backed by prominent investors such as the International Finance Corp., Novartis, and the Bill and Melinda Gates Foundation, Adjuvant draws upon a global network of scientists, public health experts, biopharmaceutical industry veterans, and development finance professionals to identify and execute upon new investment opportunities.
Adjuvant finances promising new vaccines, therapeutics, diagnostics, and medical devices for historically overlooked indications such as malaria, cholera, Lassa fever, and postpartum hemorrhage, among others, with a commitment to make these interventions accessible to those who need them most in low- and middle-income countries.
Themis is developing immunomodulation therapies for infectious diseases and cancer.
Through advanced understanding of immune system mechanisms, the company has built a sophisticated and versatile technology platform for the discovery, development and production of vaccines as well as other immune system activation approaches.
Initially focused on preventing infectious diseases, Themis has demonstrated the potential of its versatile platform through the rapid and successful completion of Phase 2 and near-term entry into Phase 3 clinical development for a vaccine against Chikungunya, a debilitating disease with global outbreak potential.
Funded to date by leading venture capital firms, Themis has also gained prestigious non-dilutive funding for emerging infectious disease indications.
The company will apply its platform and commercial manufacturing capabilities to diseases with high market potential both alone and for its partners.
Poolbeg PHarma plc receives notice of allowance for POLB 001 patent
RedHill Biopharma secures USPTO Patent for Talicia, extending protection through 2034
Micron Biomedical names new scientific advisor to CEO
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial